Edition:
United Kingdom

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

101.50USD
4:53pm GMT
Change (% chg)

$-3.70 (-3.52%)
Prev Close
$105.20
Open
$105.50
Day's High
$106.30
Day's Low
$101.40
Volume
45,629
Avg. Vol
236,098
52-wk High
$136.90
52-wk Low
$28.35

Chart for

About

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous))... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $4,516.76
Shares Outstanding(Mil.): 37.21
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

* PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS

11 Dec 2017

BRIEF-PUMA BIOTECHNOLOGY, SPECIALISED THERAPEUTICS ASIA AGREE TO COMMERCIALIZE NERLYNX IN SOUTH EAST ASIA

* PUMA BIOTECHNOLOGY AND SPECIALISED THERAPEUTICS ASIA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN AUSTRALIA, NEW ZEALAND AND SOUTH EAST ASIA

22 Nov 2017

BRIEF-Puma Biotechnology reports Q3 adj. loss per share $1.36

* Puma Biotechnology reports third quarter 2017 financial results

09 Nov 2017

BRIEF-Puma Biotechnology secures $100 mln term loan from Silicon Valley Bank and Oxford Finance

* Puma Biotechnology secures $100 million term loan from Silicon Valley Bank and Oxford Finance

02 Nov 2017

Former Puma Biotech executive pleads guilty to insider trading

BOSTON, Nov 2 A former Puma Biotechnology Inc executive pleaded guilty on Thursday to U.S. charges that he traded on inside information ahead of announcements by the biopharmaceutical company about a drug it was developing to treat breast cancer.

02 Nov 2017

BRIEF-Puma Biotechnology reports Q2 loss per share $2.10

* Puma Biotechnology reports second quarter 2017 financial results

09 Aug 2017

U.S. FDA approves Puma Biotech's breast cancer treatment

The U.S. Food and Drug Administration (FDA) on Monday approved Puma Biotechnology Inc's experimental breast cancer drug that lowers the risk of the disease returning after initial treatment.

17 Jul 2017

UPDATE 2-U.S. FDA approves Puma Biotech's breast cancer treatment

July 17 The U.S. Food and Drug Administration (FDA) on Monday approved Puma Biotechnology Inc's experimental breast cancer drug that lowers the risk of the disease returning after initial treatment.

17 Jul 2017

BRIEF-U.S. FDA approves Puma's Nerlynx for extended adjuvant treatment of HER2-positive early stage breast cancer

* U.S. Food and Drug Administration approves Puma's Nerlynx (neratinib) for extended adjuvant treatment of HER2-positive early stage breast cancer

17 Jul 2017

Earnings vs. Estimates